

LJMU Research Online

Kunda, NK, Somavarapu, S, Gordon, SB, Hutcheon, GA and Saleem, IY

Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery

https://researchonline.ljmu.ac.uk/id/eprint/126/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Kunda, NK, Somavarapu, S, Gordon, SB, Hutcheon, GA and Saleem, IY (2013) Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery. PHARMACEUTICAL RESEARCH, 30 (2). pp. 1-17. ISSN 0724-8741

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

http://researchonline.ljmu.ac.uk/



Dear Author

Here are the proofs of your article.

- This article has a short turn-around time. We need to receive your corrections within 48 hours. If we do not receive your corrections within 48 hours, we will send you a reminder. Succeeding reminders will be sent every 24 hours until we receive your corrections.
- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and email the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- Check the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- Check the questions that may have arisen during copy editing and insert your answers/ corrections.
- Check that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- Your article will be published **Online First** approximately three working days after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

http://dx.doi.org/10.1007/s11095-012-0891-5

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to: <u>http://www.springerlink.com.</u>

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

Metadata of the article that will be visualized in OnlineFirst

1	Article Title	Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery			
2	Article Sub- Title				
3	Article Copyright - Year		Springer Science+Business Media New York 2012 (This will be the copyright line in the final PDF)		
4	Journal Name	Pharmaceutical	Research		
5		Family Name	Saleem		
6		Particle			
7		Given Name	Imran Y.		
8		Suffix			
9	Corresponding	Organization	Liverpool John Moores University		
10	Author	Division	Formulation and Drug Delivery Research, School of Pharmacy and Biomolecular Sciences		
11		Address	James Parson Building, Byrom Street, Liverpool L3 3AF, UK		
12		e-mail	I.Saleem@ljmu.ac.uk		
13		Family Name	Kunda		
14		Particle			
15		Given Name	Nitesh K.		
16		Suffix			
17	Author	Organization	Liverpool John Moores University		
18		Division	Formulation and Drug Delivery Research, School of Pharmacy and Biomolecular Sciences		
19		Address	James Parson Building, Byrom Street, Liverpool L3 3AF, UK		
20		e-mail			
21		Family Name	Somavarapu		
22		Particle			
23	Author	Given Name	Satyanarayana		
24		Suffix			
25		Organization	University College London		
26		Division	Department of Pharmaceutics, School of Pharmacy		

27		Address	London, UK
28		e-mail	
29		Family Name	Gordon
30		Particle	
31		Given Name	Stephen B.
32		Suffix	
33	Author	Organization	Liverpool School of Tropical Medicine
34		Division	Respiratory Infection Group
35		Address	Liverpool, UK
36		e-mail	
37		Family Name	Hutcheon
38		Particle	
39		Given Name	Gillian A.
40		Suffix	
41	Author	Organization	Liverpool John Moores University
42		Division	Formulation and Drug Delivery Research, School of Pharmacy and Biomolecular Sciences
43		Address	James Parson Building, Byrom Street, Liverpool L3 3AF, UK
44		e-mail	
45		Received	11 June 2012
46	Schedule	Revised	
47		Accepted	18 September 2012
48	Abstract	alternate route f Immunization th and systemic im powder state cal and availability liquid-based vac reach the respira of uptake by rele of antigens to th (APCs), the denor response and th generated immu	tine delivery has gained significant attention as an for vaccination without the use of needles. Through the pulmonary route induces both mucosal munity, and the delivery of antigens in a dry in overcome some challenges such as cold-chain of medical personnel compared to traditional ccines. Antigens formulated as nanoparticles (NPs) atory airways of the lungs providing greater chance evant immune cells. In addition, effective targeting the most 'professional' antigen presenting cells dritic cells (DCs) yields an enhanced immune e use of an adjuvant further augments the une response thus requiring less antigen/dosage to ation. This review discusses the pulmonary delivery thods of preparing NPs for antigen delivery and
		targeting, the in	nportance of targeting DCs and different techniques outlating dry powders suitable for inhalation.

50 Foot note information

Pharm Res DOI 10.1007/s11095-012-0891-5

32

4

5

7 8

11

Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery

Nitesh K. Kunda • Satyanarayana Somavarapu • Stephen B. Gordon • Gillian A. Hutcheon • Imran Y. Saleem

9 Received: 11 June 2012 / Accepted: 18 September 2012
 10 © Springer Science+Business Media New York 2012

ABSTRACT Pulmonary vaccine delivery has gained significant 12attention as an alternate route for vaccination without the use of 13needles. Immunization through the pulmonary route induces 14both mucosal and systemic immunity, and the delivery of anti-15gens in a dry powder state can overcome some challenges such 16as cold-chain and availability of medical personnel compared to 17 traditional liquid-based vaccines. Antigens formulated as nano-18 particles (NPs) reach the respiratory airways of the lungs pro-19viding greater chance of uptake by relevant immune cells. In 2021addition, effective targeting of antigens to the most 'professional' 22antigen presenting cells (APCs), the dendritic cells (DCs) yields an enhanced immune response and the use of an adjuvant 23further augments the generated immune response thus requir-24ing less antigen/dosage to achieve vaccination. This review 2526discusses the pulmonary delivery of vaccines, methods of preparing NPs for antigen delivery and targeting, the importance of 2728targeting DCs and different techniques involved in formulating dry powders suitable for inhalation. 29

30 KEY WORDS antigen presenting cells · dendritic cells ·
 31 dry powder · polymeric nanoparticles · pulmonary delivery of
 32 vaccines

N. K. Kunda · G. A. Hutcheon · I. Y. Saleem (⊠) Formulation and Drug Delivery Research, School of Pharmacy and Biomolecular Sciences Liverpool John Moores University James Parson Building, Byrom Street Liverpool L3 3AF, UK e-mail: I.Saleem@ljmu.ac.uk

S. Somavarapu Department of Pharmaceutics, School of Pharmacy University College London London, UK

S. B. Gordon

Respiratory Infection Group, Liverpool School of Tropical Medicine Liverpool, UK

ABBREVIATIONS

	TATIONS	00
AMs	Alveolar macrophages	36
APCs	Antigen presenting cells	38
BAL	Bronchoalveolar lavage	39
CLRs	C-type lectin receptors	42
DCs	Dendritic cells	43
DPI	Dry powder inhalations	46
FD	Freeze-drying	48
HLA	Human leukocyte antigen	30
ILs	Interleukins	52
LN	Lymph node	53
MHC	Major histocompatibility complex	56
MN	Mannan	58
NPs	Nanoparticles	69
PCL	Poly-E-caprolactone	62
PEG	Polyethylene glycol	63
PEI	Polyethyleneimine	66
PLA	Polylactide or poly-L-lactic acid	68
PLGA	Poly lactic-co-glycolic-acid	60
PRRs	Pattern recognition receptors	72
PVA	Polyvinyl alcohol	73
SCF	Supercritical fluid	76
SD	Spray-drying	78
SFD	Spray-freeze drying	2 0
TLRs	Toll-like receptors	82
TMC	N-Trimethyl chitosan	83
VLPs	Virus-like particles	86
		. .

INTRODUCTION

New therapeutic biopharmaceuticals have made it possible 89 to treat and/or prevent many diseases which were untreatable a decade ago (1). The majority of these biopharmaceuticals are administered via parenteral routes because 92 they are degraded by acid and proteases in the stomach or 93

88

have high first-pass metabolism and as such are not suitable 94for oral delivery. The formulation of biopharmaceuticals in 95non-invasive delivery systems in order to make them more 96 97 acceptable to patients has gained significant attention but the 98 pharmaceutical challenges are stability, integrity and effectiveness within the therapeutic dose (1,2). The leading non-99100 invasive systems are buccal, nasal, pulmonary, sublingual and transdermal routes-this review will focus on the pulmo-101 nary route and on vaccine delivery in particular. 102

Pulmonary delivery of vaccines has gained major atten-103104tion for achieving both mucosal and systemic immunity (3). 105 An optimum formulation containing antigens in the dry state as nanoparticles (NPs) can result in greater stability 106and a better immune response compared to traditional 107 liquid-based vaccines (3). NPs as colloidal carriers offer 108protection of biopharmaceuticals against degradation, and 109 targeted delivery to specific sites of action. NPs can be 110111 developed with variable physico-chemical characteristics 112such as size, structure, morphology, surface texture and composition, and thus can be delivered either orally, paren-113terally or locally (4). 114

This review discusses the pulmonary delivery of vaccines, 115116 methods of preparing NPs, the importance of targeting dendritic cells (DCs) (antigen presenting cells-APCs) and different 117techniques involved in making dry powders suitable for inha-118 119lation. Progress in the delivery of biopharmaceuticals via buccal (5–7), nasal (8), sublingual (9) and transdermal (10) 120routes has previously been reported elsewhere and is beyond 121 122the scope of this review.

123 Since the term 'vaccination' was coined by Edward Jenner in 1796, it has been arguably the most important 124125scientific advance in the battle against infectious disease (11). According to the World Health Organization (WHO), 126around 2.5 million children's lives are saved each year due 127128to the availability of vaccines against a variety of antigens 129(12). However, in low and middle income countries (LMIC) 130 a lack of infrastructure such as cold-chain and trained med-131ical personnel essential for the administration of traditional liquid-based vaccine formulations, means that many eligible 132children and adults are not vaccinated (12). Table I below 133134provides a list of reported cases by disease according to World Health Statistics (WHS) 2011 (13). Hence, there is 135a global need to develop effective and reliable vaccine 136137strategies that are non-invasive, easily accessible and affordable (14). To address the issues with liquid-based vaccine 138formulations in LMIC, non-invasive routes of delivery, 139140which do not have the requirements of cold-chain or trained personal are being investigated (3). 141

Of all the non-invasive routes of delivery, pulmonary
delivery can overcome some of the current challenges of
vaccination such as invasiveness, accessibility, and vaccine
stability and integrity by delivering vaccines as dry powder
inhalations (DPI) (14). In addition, the pulmonary route has

149

177

 Table I
 List of Reported Cases by Disease According to World Health
 t1.1

 Statistics (WHS) 2011

Disease	Reported Cases (WHS 2011) ^a	t1.2
Diptheria	857	t1.3
Malaria	81,735,305 (1990–2009)	t1.4
Measles	222,318	t1.5
Mumps	546,684	t1.6
Tetanus	9,836	t1.7
Tuberculosis	5,797,317	t1.8
Pneumonia (Children <5 years)	~1,400,000 (18% of all child deaths in 2008) (120)	t1.9

^a Data provided not necessarily for the year 2011, more details at http:// www.who.int/whosis/whostat/2011/en/index.html

gained much attention as it is the main entry portal for 147 pathogens (2,15). 148

PULMONARY VACCINE DELIVERY

Pulmonary delivery as a route of drug administration can be 150traced back 4000 years to India where people suffering from 151cough suppressed it by inhaling the leaves of Atropa Belladon-152na (16). Later in the 19th and 20th centuries, people suffer-153ing from asthma smoked cigarettes containing tobacco and 154stramonium powder to alleviate their symptoms (16). The 155first inhaling apparatus for dry powder delivery was patent-156ed in London in 1864 (17). Since then much progress has 157been made in developing devices such as nebulizers, 158metered dose inhalers and DPIs for delivery of therapeutics. 159With recent advancements in pulmonary delivery devices 160and recombinant protein technology the first peptide DPI 161formulation, Exubera (Nektar/Pfizer), was approved and 162released into the market in January 2006. This was soon 163withdrawn for several reasons including bulkiness of the 164device, complicated administration, contraindication in 165smokers and insufficient evidence with regulatory bodies 166regarding the patients preference of Exubera (inhaled dosage 167form) compared to other dosage forms (18). This led, however, 168to further research and development of DPI of biopharma-169ceuticals, and currently many investigations are being pursued 170by the pharmaceutical industry such as the AIR system 171(Alkermes/Eli Lilly), the Technosphere system (Mannkind) 172and Kos inhaled insulin (Kos Pharm/Abbott) for Type I/II 173diabetes, and Granulocyte-colony-stimulating factor (G-CSF) 174for Neutropenia (Amgen) (19). This has been followed by 175investigations into DPI of vaccines (20-24). 176

Anatomy of the Human Lung

The human lung, weighing about 1 kg, is divided by the 178 pleural membranes into three lobes on the right and two 179

Nanocarriers Targeting Pulmonary Dendritic Cells

180lobes on the left (25). Once inhaled, the air passes through the nose and mouth, from the larynx to trachea and to the 181series of around 16 generations of conductive bronchi and 182183bronchioles (25,26). From the 17th generation of bron-184 chioles, alveoli begin to appear in the walls (respiratory airways) and by the 20th generation of airways, the entire 185186 walls are composed of alveoli, commonly referred to as alveolar ducts. At the 23rd generation, the alveolar 187 ducts end in blind sacs, lined with alveoli, and are referred 188 189to as alveolar sacs (Fig. 1) (25-27). It is estimated that 190on an average a human lung consists of about 300 million 191 alveoli providing a surface area of exchange of 80-90 sg. m (25, 28).192

The submucosal glands and the 'goblet cells' (present on 193the bronchial surface) secrete mucus onto the bronchial sur-194195faces. The submucosal glands also help in producing an elec-196 trolyte solution on which the mucus rests. The mucus covering 197the airways is transported towards the mouth with the coor-198dinated movement of cilia present on top of the ciliated columnar cells. This mucus transported to the mouth is then 199swallowed. This process of mucus movement from the bron-200 chial surfaces to the mouth for swallowing is mainly responsi-201202 ble for removing any foreign material that lands on the bronchial surfaces (25). 203

204 The alveoli and the pulmonary capillaries are separated by 205a barrier composing of endothelial cells, interstitial space, and pneumocytes (pulmonary epithelial cells). The pneumocytes 206


based on size.

212

are divided into two types, type I and type II cells. Type I are 207very flat and cover the alveolar surface whereas type II are 208irregularly shaped containing lamellar bodies that are secreted 209 as surfactant, and they can further divide and produce type I 210and type II cells (25). 211

Lung as a Delivery Site for Drugs

The lung is an excellent choice for the delivery of biophar-213maceuticals for the treatment of both local and systemic 214disorders as it offers several advantages such as; large surface 215area (80 sq. m), dense vasculature, rapid absorption leading 216to an immediate onset of action, thin alveolar epithelium, 217less enzymatic activity than gut and a high capacity for 218solute exchange (29). With regards to the delivery of vac-219cines, a high density of APCs including alveolar macro-220 phages (AMs), DCs and B cells represent an ideal target to 221induce a strong immune response resulting in both mucosal 222and systemic immunity (14). Recent research has con-223firmed that the induction of an immune response at one 224mucosal site elicits an immune response at distant muco-225sal sites by mucosal lymphocyte trafficking leading to 226both mucosal and systemic immunization (15,30). There 227is some evidence that mucosal immunization may also 228reduce the dosage required to achieve the desired immunity 229compared to liquid formulations administered via the 230parenteral route (3). 231



232 **Pulmonary vs Parenteral Vaccine Delivery**

233 In development of novel anti-tuberculosis vaccines, Ballester 234M et al. demonstrated, that inhaled vaccine compared fa-235vorably to an intradermal route of delivery. In particular, vaccination with NP-Ag85B and immune-stimulatory oligo-236 237nucleotide CpG as a Th1-promoting adjuvant via the pulmonary route modified the pulmonary immune response 238and provided significant protection following a Mycobacterium 239 tuberculosis (Mtb) aerosol challenge (31). 240

241Muttil P et al. successfully prepared poly lactic-co-242 glycolic-acid (PLGA) NPs entrapping diphtheria CRM-197 antigen (CrmAg) with a size of 200±50 nm by the emulsi-243fication solvent diffusion and double-emulsion methods. 244The NPs were then spray-dried with L-leucine and the 245246 resulting spray-dried powders of formalin-treated/untreated CrmAg nanoaggregates were delivered to the lungs of guin-247ea pigs. This study evaluated the immune response elicited 248249in guinea pigs following pulmonary and parenteral immunizations with the dry powders and the highest titer of serum 250IgG antibody was observed in guinea pigs immunized by the 251252intramuscular route whereas high IgA titers were observed 253for dry powder formulations administered by the pulmonary route. This demonstrates that pulmonary immunization 254with dry powder vaccines leads to a high mucosal immune 255256response in the respiratory tract and sufficient neutralizing 257antibodies in the systemic circulation to provide protection against diphtheria (32). 258

An ideal vaccine formulation for mass vaccination would induce the desired immunity upon administration of a single dose. Moreover, it is important to target APCs like DCs to illicit a strong and durable immune response with a single dose aimed at both systemic and mucosal immunity (33).

264 Dendritic Cells

265Dendritic cells (DCs) were first identified in 1868 by Paul 266Langerhans in the basal layer of the epidermis (34). However, it took more than a century to properly identify them 267268as white blood cells related to macrophages and monocytes, 269 and to understand their importance in the control of immunity (34,35). In 2011, the Nobel Prize in Physiology or 270Medicine was awarded to Ralph M. Steinman for his dis-271272covery of DCs and their role in adaptive immunity paving the way for more research in the field of immunity and 273vaccines (36). It has become evident over the years that 274275DCs are APCs, true 'professionals' (37) with exceptional 276capability to internalize, process and present antigens through major histocompatibility complex (MHC) class I 277and II pathways. DCs induce a strong immune response 278279by activating naïve T-cells which are produced in the bone 280marrow and have the capability to respond to novel patho-281gens that have not been processed before (38,39). The role of DCs in initiating a primary immune response has now 282 been shown to be greater than the role played by macro-283 phages and the B-cells (40). 284

The lung is armed with an intricate network of DCs that 285can be found throughout the conducting airways, lung 286interstitium, lung vasculature, pleura, and bronchial lymph 287nodes (41, 42). It is now apparent that there are at least five 288different subsets of DCs in the murine lung; resident DCs, 289plasmacytoid DCs, alveolar DCs, inflammatory DCs and 290 interferon-producing killer DCs (41,42). The data for the 291subsets of DCs in the human lung is rare (43) owing to the 292need to obtain lung tissue, as they are not found in the 293bronchoalveolar lavage (BAL) fluid. However, studies on 294the human AMs are common as they are readily obtained 295from BAL (44). The AMs are primarily phagocytes with 296poor APC function and live in the air space, whereas im-297 mature DCs have high APC function but lower phagocytic 298function and live mainly in the interstitium (45). In the 299 human lung, the mucosal surface in the conducting airways 300 consists of ciliated epithelial cells, interspersed goblet cells, 301 macrophages and DCs (46). The DC population in this 302 region is mainly composed of myeloid DCs (mDCs), how-303 ever, a fraction of plasmacytoid DCs (pDCs) can be found 304 (46). These mDCs have a high capability for antigen uptake 305but less ability to stimulate the T cells (46). Moreover, the 306 human DCs are generated from haematopoietic stem cells, 307 mDCs from bone marrow-derived monocytic precursors 308 and pDCs from lymphoid progenitors (34). The mDCs 309 and pDCs are activated by a different set of pathogenic 310 stimuli making them functionally distinct reflected by the 311different expression of cell surface receptors such as Toll-like 312receptors (TLRs) (34,46). The lung parenchyma consisting 313of lung interstitium, respiratory and terminal bronchioles, 314and alveoli is mainly composed of 80% macrophages with 315 rest being DCs and T cells. The 'immature' resident DCs 316 are highly capable of detecting, capturing and processing 317 the encountered antigen (34, 46). 318


The human DCs are identified by over expression of 319 human leukocyte antigen (HLA) DR (major histocompati-320 bility complex class II) with the absence of monocyte, lym-321phocyte, natural killer cell and granulocyte lineage markers 322 (43). In addition, the specific markers for identifying the 323 mDCs include CD11c⁺, CD1a⁺, BDCA-1⁺, BDCA-3⁺, 324 HLA-DR⁺ whereas for the pDCs they are CD11c⁻, HLA-325 DR⁺, BDCA-2⁺ and CD123⁺ (43,46,47). 326


Inhaled antigens or antigen particulates are believed to 327 encounter the wide spread DC network that lines the alve-328 olar epithelium and are subsequently taken up by cellular 329 processes extending in to the alveolar lining fluid (33). Anti-330 gens are then processed and fragments of antigenic peptides 331are presented on the surface through MHC class I and II 332 pathways for recognition by the T-cell receptors present on 333 T-cells (40). This process is often referred to as antigen 334

Nanocarriers Targeting Pulmonary Dendritic Cells

335 presentation and typically takes place in the regional lymph node after chemokine dependent migration of the antigen 336 loaded DC. Also, APCs perceive danger signals from cells 337 338 and offer co-stimulatory signals (48) through co-stimulatory 339 molecules present on their surface for recognition by receptors on recirculating T-cells to initiate an immune response 340 341in the lymph node (40). Upon encountering the danger signals, immature DCs change to a mature stage where they 342 present the antigen on their surface. This step is usually 343 344 concurrent with the migration of DCs from peripheral tissue 345to the lymph node for T-cell activation (Fig. 2). It is believed 346 that soon after antigen presentation, the DCs undergo apoptosis in the lymph nodes (40). 347

Antigen uptake by DCs occurs by macro-pinocytosis. 348 receptor-mediated endocytosis (macrophage mannose recep-349 tor) and/or phagocytosis (49-52). Recent research by Foged et 350 al. has shown that both particle size and surface charge of the 351material to be delivered plays an important role in determining 352 the uptake by human DCs derived from blood. Furthermore, it 353 was recognised that for optimal uptake by DCs the preferred 354 particle size was 0.5 µm (diameter). Uptake of large particles 355 $(\sim 1 \,\mu m)$ was greatly enhanced when they displayed a positive 356 surface charge (53). In addition, a study conducted by Mano-357lova et al. revealed that upon intracutaneous injection of poly-358 styrene beads of varying sizes the large particles (500-2000 nm) 359 associated with DCs from the site of injection and depended 360





AUTH109RthS91PrR#1000P2012

largely on them for cellular transport, whereas small particles
(20–200 nm) and virus-like particles (VLPs) (30 nm) drained
freely to the lymph nodes (LNs) and were present in LNresident DCs and macrophages (54). However, this cannot be
directly compared to pulmonary delivery as the DCs in the lung
differ from those of the skin.

367 Targeting Antigen to the DC

Antigen can be targeted to DCs, for enhanced immune response, by making particles that bind to the specific receptors
expressed on the DC surface (49–51). Effective targeting of
vaccines to the DCs results in the possibility of a reduced
vaccine dose, less side effects, improved efficacy and enhanced
immune response (40).

Vaccines can be targeted to DCs in different ways (40, 37455-57). DCs contain pattern recognition receptors (PRRs) 375that aid in detecting the presence of a pathogen through 376 377 interaction with pathogen-associated molecular patterns. More specifically, C-type lectin receptors (CLRs), a type of 378 PRR, bind to sugar moieties (e.g., mannose, glucan) in a 379calcium-dependent manner present on the pathogen's sur-380 381 face. This leads to antigen internalization through receptor, 382 mediated endocytosis resulting in antigen presentation to Tcells (58,59). Vaccines can also be targeted to DCs with anti-383 384 bodies having an affinity towards specific receptors present on their surface (e.g. anti-DEC205, anti-CD11c), internalization 385 through phagocytosis and conjugation of danger signals that 386 effectively bind to Toll-like receptors (TLRs) or cytokine 387 receptors thereby inducing DC maturation (40,55). Table II 388 389 lists some formulations that have been effectively targeted to DCs for an enhanced immune response. There are currently 390

t2.1 **Table II** Examples of Formulations Targeting Dendritic Cells (DCs)

393

no publications that establish targeting of pulmonary DCs 391 through pulmonary delivery of dry powder vaccines. 392

Nanoparticles for Inhalation

Generally nanoparticles (NPs) are referred to as particles in the 394 size range of 1-100 nm, however for drug delivery NPs larger 395 than 100 nm are required for efficient drug loading, and have 396 been in use for the last 40 years (60). NPs are used as drug 397 carriers either by encapsulating, dissolving, surface adsorbing 398or chemically attaching the active substance (60). NPs have a 399 large surface area-to-volume ratio and also an increased satu-400 ration solubility thus favoring application in the field of drug 401 delivery. In delivery of NPs to the lung by inhalation, deposition 402 takes place through impaction, sedimentation, interception or 403 diffusion (Table III) depending on particle size, density, airflow, 404 breathing rate, respiratory volume and the health of the indi-405vidual (61,62). These are discussed in greater detail by Smyth 406 HDC et al. (63) and definitions are summarized in Table III. 407

The deposition of particles in the lungs is evaluated using the 408 aerodynamic particle size, which is defined as the diameter of a 409 sphere (density-1 g/cm³) in air that has the same velocity as the 410 particle in consideration (60). This is defined by the equation 411

$$d_a = d_g \sqrt{\rho/\rho_a}$$

where ρ is the mass density of the particle, ρ_a is the unit density 412 (1 g/cm3) and d_g is the geometric diameter. 414

Particles greater than 10 μ m (d_a) in size are commonly 415 impacted in the throat or sedimented in the bronchial 416 region whereas particles less than 1 μ m (d_a) in size are 417 exhaled and not likely to be deposited in the alveolar region. 418 It is expected that particles in the size range of 1 to 5 μ m (d_a) 419

t2.2	Formulation	Target	Model drug	Model	Ref
t2.3	Polyanhydride NPs with dimannose	Mannose receptor CD206	NA	In vitro	(58)
t2.4	MN-decorated PLGA NPs	Mannose receptor CD206	NA	In vitro	(121)
t2.5	PLGA NPs	DEC-205 receptor	Ovalbumin	Mice	(122)
t2.6	PLGA NPs	Humanized targeting antibody hD1 (DC-SIGN)	FITC-TT/DQ Green BSA	In vitro	(123)
t2.7	PLGA NPs coated with streptavidin	gp120, ManLAM, Lex, aDC-SIGN 1, aDC-SIGN 2, aDC-SIGN 3	DQ-BSA, gp100 ₂₇₂₋₃₀₀ and FITC-TT	In vitro	(56)
t2.8	Carbon magnetic NPs (CMNPs)	Endocytosis	Hen egg lysozyme (HEL)	Mice	(124)
t2.9	Polystyrene and PLGA microparticles	CD40, Fcg, $\alpha(v)\beta$ 3 and $\alpha(v)\beta$ 5	NA	In vitro	(125)
t2.10	Acid degradable particles	DEC-205 receptor	Ovalbumin	Mice	(124)
t2.11	PAMAM dendrimer	Mannose receptor CD206	Ovalbumin	Mice	(126)
t2.12	Liposome (with tri-mannose) (L-Phosphatidylcholine + M3-DPPE)	Mannose receptor CD206	FITC-Ovalbumin	In vitro	(127)
t2.13	Niosomes (coated with polysaccharide o-palmitoyl MN)	Mannose receptor CD206	ТТ	Albino Rats	(128)

M3- DPPE trimannose-dipalmitoylphosphatidylethanolamine, ManLAM Mannosylated lipoarabinomannan, MN Mannan, Niosomes Sorbiton Span 60, cholesterol, stearylamine, PAMAM Polyamidoamine, PLGA poly lactic-co-glycolic-acid, TT Tetanus Toxoid, NA Not Applicable

442

Impaction	The delivered particles, due to inertia, do not change their path and as the airflow changes with bifurcations they tend to get impacted or
·	the airway surface. This is mostly experienced by large particles and is highly dependent on the aerodynamic properties of the particles
Sedimentation	The settling down of the delivered particles. This is generally observed in the bronchioles and alveoli.
Interception	This occurs when particles, due to their shape and size, interact with the airway surface and is experienced when the particles are close to the airway wall.
Diffusion	Is the transport of particles from a region of higher concentration to lower concentration, is observed for particles that are less than 0.5 μ m in diameter and occurs in the regions where the airflow is low. This is highly dependent on the geometric diameter of the particles.

Nanocarriers Targeting Pulmonary Dendritic Cells

420 avoid deposition in the throat and reach the respirable airways (Fig. 1) and the periphery of the lung (61). Particles less than 421422 1 µm (referred to as NPs) are driven by diffusion and are most 423 likely to be exhaled, hence they are therefore often delivered within microparticles. In addition, upon long term storage 424 NPs tend to aggregate due to high particle-particle interac-425426 tions (60). Microparticles prepared from NPs are typically about 1-5 µm in size and usually also encompass inert phar-427 428 maceutical excipients (sugars, amino acids etc.) that act as carriers. The excipients dissolve upon encountering the respi-429430ratory environment thereby releasing the NPs.

431 Different types of NPs have been explored for vaccine
432 delivery and antigenic peptides or proteins are either surface
433 adsorbed or encapsulated within the NPs. Table IV outlines
434 some types of NPs evaluated for vaccine delivery.

This review focuses on polymer-based NPs because they have been extensively investigated as vaccine delivery systems due to their enhanced uptake by phagocytic cells, thereby facilitating antigen internalization and presentation in DCs. In addition, both antigen and materials that augment the immune response (adjuvants) can be encompassed together in nanocomposite microparticles, resulting in their simultaneous delivery (64).

Polymer-based Nanoparticles

Wide varieties of polymers, both natural and synthetic, have 443 been exploited to form biodegradable NPs. In addition, some 444 of the polymers can act as adjuvants themselves (65). Natural 445polymers that have been widely investigated for formulating 446 NPs include albumin, alginate, chitosan, collagen, cyclodex-447 trin and gelatin; synthetic polymers include polyesters, poly-448 lactides, polyacrylates, polylactones and polyanhydrides 449(66,67). While natural polymers have a relatively short dura-450tion of drug release, synthetic polymers can be tailored to 451 release the drug over days to several weeks allowing the usage 452of a single dose rather than multiple doses (65). 453

Biodegradable polymers have gained significant attention 454for the preparation of NPs for drug delivery and are often 455favored as they offer several advantages such as controlled or 456sustained drug release, biocompatibility with the surrounding 457tissues and cells, low toxicity, are nonthrombogenic and are 458more stable in the blood (66,68). Biodegradable polymer-based 459 NPs also offer an additional advantage for vaccine delivery 460 systems by acting as adjuvants and aiding in activating both 461 cellular and humoral immune responses (69). It has been 462

t4.1 **Table IV** Examples Of Nanoparticles Currently Being Evaluated For Vaccine Delivery

t4.2	Nanoparticles	Description	Size	Vaccine	Ref
t4.3	Micelles (Peptide Cross-linked micelles-PCMs)	PCMs are composed of block copolymers and encapsulate immuno stimulatory DNA in the core and bind peptide antigens through disulphide linkages. In the presence of a high concentration of glutathione they deliver antigenic peptides and immuno stimulatory DNA to APCs	50 nm	HIV peptide vaccine	(129)
t4.4	Liposomes	Dimyristoyl phosphatyl-choline (DMPC):cholesterol(CH)-(7:3) liposomes were prepared by dehydration-rehydration followed by freezing-thawing method. The enzyme, GUS, was successfully encapsulated and showed encouraging activity following aerosolization	~ 6.4 µm (with 1:4 liposome:mannitol)	β-Gluc-uronidase – enzyme (GUS)	(130)
t4.5	Polymersomes	poly(g-benzyl-L-glutamate)-K (PBLG50-K) polymersomes were prepared by the solvent removal method and influenza hemagglutinin (HA) was surface adsorbed. When tested <i>in vivo</i> , polymersomes acted as an immune adjuvant and showed an improved immunogenicity.	250 nm	influenza hemagglutinin (HA) – subunit vaccine	(3)
t4.6	Polymer-based	Porous poly-L-lactic acid (PLA) and poly lactic-co-glycolic-acid (PLGA) NPs were prepared by a double-emulsion-solvent evaporation method encapsulating HBsAg and were tested for pulmonary delivery in rat spleen homogenates. The study demonstrated enhanced immune responses.	474–900 nm	hepatitis B surface antigen (HBsAg)	(24)

reported that upon phagocytosis by APCs, such as DCs, these
NPs release the antigen intercellularly and elicit CD8+ and
CD4+ T cell responses (70).

466 In a study performed by Bivas-Benita M et al., the potential of 467 enhanced immunogenicity upon pulmonary delivery of DNA encapsulated in chitosan NPs was evaluated. Chitosan-DNA 468 469 NPs were prepared by the complexation-coacervation method and the resultant DNA-loaded NPs had an average size of $376 \pm$ 47059 nm (n=5), zeta-potential of 21 ± 4 mV (n=5) and a loading 471472efficiency of 99%. Pulmonary administration of the chitosan-473DNA NPs was shown to induce increased levels of IFN-y 474 secretion compared to pulmonary delivery of the plasmid in solution via the intramuscular immunization route. This indi-475cates the plausibility of achieving pulmonary delivery of DNA 476 vaccines with increased immunogenicity against tuberculosis 477 478 compared to immunization through intramuscular route (71).

479 The polylactides PLA and PLGA are the most broadly investigated synthetic polymers in the field of drug delivery 480 481 (66,67,72). These are rapidly hydrolyzed upon implantation into the body and are eventually removed by the citric acid 482 cycle. The hydrolyzed products form at very slow rate and 483include lactic acid and glycolic acid which are biologically 484 485 compatible and easily metabolized making them safe and non-toxic (66,73). However, the acidic degradation products 486can cause problems by eliciting inflammation and also a 487 488 reduction in pH within the microparticles resulting in the hydrolysis of the biopharmaceuticals (74). 489

Muttil et al. prepared novel NP-aggregate formulations using 490 poly(lactic-co-glycolic acid) (PLGA) and recombinant hepatitis 491B surface antigen (rHBsAg) and showed that the dry powder 492formulations elicited a high mucosal immune response after 493494 pulmonary immunization of guinea pigs without the need for adjuvants. They prepared three different formulations of dry 495powders by spray-drying with leucine, (1) rHBsAg encapsulated 496 497 within PLGA/polyethylene glycol (PEG) NPs (antigen NPs, AgNSD), (2) a physical mixture of rHBsAg and blank PLGA/ 498PEG NPs (antigen NP admixture (AgNASD), and (3) rHBsAg 499500encapsulated in PLGA/PEG NPs with free rHBsAg (antigen NPs plus free antigen). All the particles had mass median 501502aerodynamic diameters (MMAD) of around 4.8 µm and a fine 503particle fraction (FPF) of 50%. After immunization the highest titre of serum IgG antibodies was observed in the control group 504immunized with alum adsorbed with rHBsAg (Alum Ag) (IM 505506route) whereas the highest IgA titres were observed for animal groups immunized with powder formulations via the pulmo-507nary route. It was also noteworthy guinea pigs immunized with 508509AgNASD dry powder exhibited IgG titers above 1,000 mIU/ ml in the serum (required 10 mIU/ml) suggesting the potential 510of administering novel dry powder formulations via the pulmo-511512nary route (75).

513 Recently a new class of biodegradable polymers, polyke514 tals, have been developed and are largely being investigated
515 for drug delivery purposes (76,77). This class of polymers

550

have non-acidic degradation products and pH-sensitive 516ketal linkages in their backbone. These polyketals offer 517several advantages for vaccine delivery such as exhibiting 518pH-dependent hydrolysis but yet are degradable in acidic 519phagolysosomes. Polyketal copolymers degrade into bio-520compatible small molecules minimizing inflammation com-521pared to PLGA. An aliphatic polyketal, poly(cyclohexane-1,4-522divl acetone dimethylene ketal) (PCADK) degrades into ace-523tone and 1,4-cyclohexanedimethanol which are both biocom-524patible, and has a hydrolysis half-life of 24 days at pH 4.5 (77). 525This was later modified to a co-polyketal termed PK3 synthe-526 sized from 1,4-cyclohexanedimethanol and 1,5-pentanediol 527 with a hydrolysis half-life of 1.8 days at pH 4.5 (64) making 528it much suitable for vaccine delivery. 529

Heffernan MJ and Murthy N successfully prepared acid-530sensitive polyketal NPs that released the loaded therapeutics in 531the acidic environments of tumors, inflammatory tissues and 532phagosomes. Polyketal NPs, 280-520 nm in diameter, were 533prepared by an oil-in-water (O/W) emulsion method using 534poly(1,4-phenyleneacetone dimethylene ketal) (PPADK), a 535new hydrophobic polymer that undergoes acid-catalysed hy-536drolvsis into low molecular weight hydrophilic compounds. 537(76). Heffernan et al. used polyketal PK3 to formulate a model 538vaccine that elicits CD8+ T cell responses. PK3 microparticles 539encapsulating ovalbumin (OVA), poly(inosinic acid)-poly(cyti-540dylic acid) (poly(I:C)) - a TLR3 (Toll like receptor) agonist and a 541double-stranded RNA analog were prepared using single 542emulsion method. PK3-OVA-poly(I:C) microparticles (1-543 $3 \,\mu\text{m}$) at a dosage of 0.01 $\mu\text{g/mL}$ were then supplied to murine 544splenic DCs and a higher percentage of IFNy-producing 545CD8+ T cells, TNF- α and IL-2 production in CD8+ T cells 546were observed than with DCs treated with PK3-OVA par-547ticles or soluble OVA/poly(I:C) implying polyketal PK3 548microparticles have potential for vaccine delivery (64). 549

Preparation of Polymer-Based Nanoparticles

Different methods have been employed to synthesize polymer-
based NPs depending on the subsequent application and type551of drug. Polymer-based NPs can either encapsulate or surface
adsorb the drug (68,78). Here we review some of the most
widely used methods to prepare polymer-based NPs. Howev-
er, a more detailed review and analysis of these methods can be
found at Reis P et al. (78) and Avnesh K et al. (68).551

Emulsification/Solvent Evaporation and Nanoprecipitation. E-558mulsification/solvent evaporation, also referred to as solvent 559emulsion-evaporation, involves the emulsification of an or-560 ganic polymer solution into an aqueous phase followed by 561the evaporation of the organic solvent (78). The polymer 562with or without the drug is dissolved in a volatile organic 563 solvent like acetone, ethyl acetate, chloroform or dichloro-564methane etc. and is then transferred into stirring aqueous 565

566 phase with or without the presence of an emulsifier or 567 stabilizer. This emulsion is then sonicated to evaporate the 568 organic solvent and form NPs (68) (Fig. 3a). The size of the 569 resultant particles can be controlled by varying the type, 570 viscosity and amount of organic and aqueous phases, stir 571 rate and temperature (78).

572Singh J et al. prepared diphtheria toxoid (DT) loaded poly-(*\varepsilon*-caprolactone) (PCL) NPs via a double emulsification 573solvent evaporation method (w/o/w) for investigating their 574575potential as a mucosal vaccine delivery system. Briefly, DT 576was added to the internal aqueous phase containing 0.25 ml 577 10% w/v polyvinyl alcohol (PVA). The solution was emulsified with the organic phase comprising 100 mg of PCL in 5785 mL of dichloromethane (DCM), using a homogenizer at 57912,000 rpm for 2 min. The formulations were then stirred 580581magnetically at ambient temperatures and pressure for 15-18 h to allow solvent evaporation and NP formation. The 582583resultant NPs were approximately 267 ± 3 nm in size with a 584zeta-potential of -2.6 ± 1.2 mV. Also, the PCL NPs induced DT serum specific IgG antibody responses significantly 585higher than PLGA (79). 586

The nanoprecipitation method is a single step method 587 588 which is usually employed for entrapping hydrophobic drug moieties. In this method, the drug and the polymer are dis-589solved in a water-miscible solvent, such as acetone, acetonitrile 590591or methanol (80). This organic phase is then added drop-wise to an aqueous phase with or without an emulsifier/stabilizer 592under magnetic stirring (68). NPs are formed due to rapid 593594solvent diffusion and the solvent is finally removed from the emulsion under reduced pressure (81) (Fig. 3b). 595

Lee JS *et al.* prepared poly(ethylene glycol)-poly(ε-caprolactone) (MPEG-PCL) NPs via a nanoprecipitation method.
Firstly, a predetermined concentration of MPEG-PCL block copolymer was dissolved in 10 mL of organic solvent (ace-599tone, acetonitrile or THF). This polymer solution was then 600 added drop wise into deionized water (100 mL) under mag-601 netic stirring. The organic solvent was then evaporated under 602 reduced pressure using a rotary evaporator, and the resultant 603 NPs were isolated from the aqueous solution. Using different 604 organic solvents and concentrations of polymer vielded NPs 605 particles between ~ 50 to 150 nm (82). 606

Emulsification and Solvent Displacement. The emulsification 607 and solvent displacement method is also known as emulsifica-608 tion solvent diffusion. This method involves the precipitation 609 of the polymer from an organic solution and subsequent 610 diffusion of the organic solvent into an aqueous phase (78). 611 The solvent that aids in the formation of emulsion must be 612 miscible with water. For example, the organic polymer solu-613 tion can be added to an aqueous phase, which often contains a 614 stabilizer, under strong stirring. Upon the formation of the 615 emulsion (O/W), a large quantity of water is added so as to 616 dilute it favoring the diffusion of additional organic solvent 617 from the dispersed droplets. This process leads to the precip-618 itation of the polymer (81). An interfacial turbulence is created 619 between the two phases as the solvent diffuses resulting in the 620 formation of smaller particles and is believed that as the water-621 miscible solvent concentration increases the NPs tend to ac-622 quire a smaller size (80) (Fig. 3c). 623

Ranjan AP et al. have recently prepared biodegradable624NPs containing indocynanine green (ICG) using chitosan625modified poly(L-lactide-co-epsilon-caprolactone) (PLCL):626poloxamer (Pluronic F68) blended polymer by an emulsifi-
cation solvent diffusion technique. PVA and chitosan were628used as stabilizers in the process of making the NPs. The
average particle size of the resultant NPs was between $146 \pm$ 630




Fig. 3 Schematic representation of a emulsification/solvent evaporation technique, b emulsification and solvent displacement technique, c salting-out technique and d nanoprecipitation technique.

631 3.7 to 260±4.5 nm and the zeta potential progressively
632 increased from -41.6 to +25.3 mV with increasing amounts
633 of chitosan (83).

634 Salting Out. The salting out method is based on the separation of a water-miscible organic phase from an aqueous solution by 635 636 adding salting out agents (78,80,84). Briefly, the polymer is dissolved in a water-miscible organic solvent such as acetone 637 or tetrahydrofuran (THF) which is then added under strong 638 stirring to an aqueous solution containing salting out agents 639640 (for example magnesium chloride, calcium chloride) and an 641 emulsifier or stabilizer to form an O/W emulsion (80,81,85). 642 This O/W emulsion is diluted by adding a large volume of water under mild stirring thus reducing the salt concentration/ 643 ionic strength and favouring the movement of the water-644 645 miscible organic solvent into the aqueous phase. This process leads to the formation of nanospheres and as a final step the 646 647 NPs formed are freed from the salting out agents either by 648 centrifugation or cross-flow filtration (80) (Fig.3d).

Konnan YN et al. prepared sub-200 nm NPs using a 649 salting out method. Typically, a solution of PLGA and 650 PLA in THF was added under mechanical stirring to an 651 652 aqueous phase containing PVA and magnesium chloride hexahydrate (MgCl₂.6H₂O) as a salting out agent forming 653 an O/W emulsion. To this, a large volume of water was 654 655 added favoring migration of the water-miscible organic solvent into the aqueous phase forming NPs which were 656 later purified by cross flow filtration (86). 657

Table V lists some of the advantages and disadvantagesof nanoparticle preparation methods (77).

661 Encapsulation or Adsorption

A high loading capacity is one of the most desired qualities of
NP-based vaccines. The main advantage of having a high
loading capacity is that the amount of polymer required to
carry the drug/vaccine is reduced (81) hence minimizing any
toxic effects from the polymer. Drugs/vaccines can be loaded
into or onto NPs using two approaches (Fig. 4) (87). The first is
encapsulation where the drug/vaccine is incorporated into the

NP at the time of preparation; the second is adsorption where669the drug/vaccine is either chemically or physically adsorbed670onto the NP after preparation.671

It is important to note that the chemical structure of the 672 drug/vaccine, the polymer and the conditions of drug loading 673 influence the amount of drug/vaccine bound to the NPs and 674 the type of interactions that occur between them (81). In addition, the encapsulation or adsorption of a drug/vaccine depends 676 on the disease to be treated or prevented, route of administration, manufacturing feasibility and economic challenges. 678

Bivas-Benita M et al. prepared PLGA-polyethyleneimine 679 (PEI) NPs by an interfacial deposition (88) method. The 680 resultant NPs were loaded with Mycobacterium tuberculosis 681 (Mtb) Antigen 85B (Ag85B) by adding the NP suspension to 682 25 µg/mL DNA plasmid solution. The characterization stud-683 ies revealed that the particle size increased from 235 to 684 275 nm when resuspended in water and 271 nm in saline with 685the mean zeta potential increase from +38.8 mV to +40.6 mV 686 respectively. The NPs greatly stimulated human DCs resulting 687 in the secretion of IL-12 and TNF- α at comparable levels to 688 that observed after stimulation using lipopolysaccharide 689 (LPS) (89). 690

Biodegradable polymer-based NPs have been widely explored and appear to be well tolerated when administered into the body. These NPs have gained significant attention and are being accepted as effective delivery systems with the development of NP based vaccines (90,91). In addition, the NP based vaccines need to be formulated appropriately, as dry powders and at low cost to help achieve effective mass vaccination. 697


Adjuvants


Modern day vaccines contain pure recombinant or synthetic 699 antigens that are less immunogenic than live or killed whole 700 organism vaccines. Thus, in order to obtain a strong im-701 mune response upon administration of antigen and provide 702 long term protection against the infection, adjuvants are 703 included within the formulation (92). Adjuvants are substan-704 ces used in combination with an antigen to produce a 705 stronger and more robust immune response than the anti-706 gen alone (93). Adjuvants also provide a depot for the 707

t5.1 \qquad Table V Advantages and Disadvantages of Nanoparticle Preparation Methods

		0 1 1		
2	Method	Advantages	Disadvantages	
3	Emulsification/Solvent Evaporation	Hydrophilic and hydrophobic drugs can be encapsulated	Agglomeration of nanodroplets during evaporation	
ł	Emulsification and Solvent Displacement	Control over the size of nanoparticles	Possibility of water-soluble drug leaking into the external aqueous phase, Large amounts of water to be removed	
5	Salting Out	High loading efficiency, Easy scale-up	Removal of electrolytes, Incompatibility of salting-out agents with drugs	
;	Nanoprecipitation	Simple, fast and reproducible, Easy scale-up, Low surfactant concentrations required	Less polymer in the organic phase	

Nanocarriers Targeting Pulmonary Dendritic Cells





Encapsulation

Adsorption

708 antigen favoring a slow release, reduce the dose of antigen 709 required to generate a strong immune response, modulate 710 the immune response, aid in targeting the APCs, and provide danger signals helping the immune system respond to 711the antigen (92–94). The selection of an adjuvant depends 712on the antigen, delivery system, route of administration and 713 714 possible side-effects. However, an ideal adjuvant should have a long shelf life and be safe, stable, biodegradable, 715economical and should not induce an immune response 716 717 against themselves (92).

Despite massive efforts over nearly 90 years into the 718research and development of adjuvants, the list of adjuvants 719 720 that are clinically approved is short. The prime reason being 721 their safety coupled with limited data on the predictability of safety using available animal models (95). The serious ad-722 723 verse events in the recent clinical trials of Merck's (96) and Novartis's (NCT00369031) (97) HIV vaccines using 724 adenovirus- and toxin-based adjuvanted delivery systems 725 726 has moved the research into further investigations in devel-727 oping nutritive adjuvanted delivery systems (Vitamins A, C, 728 D, E, flavonoids and plant oils). These may prove safer in 729 clinical trials (98,99). Table VI lists adjuvants in development 730 or licensed for human use.

Alum salts have a well-established safety record, are the
most widely used human adjuvants and are used as standards
to assess other adjuvants (92,93,95,100). Despite their wide
use their mechanism is poorly understood and thus rarely
induce human responses (92).

Wee JLK et al. used a sheep animal model to evaluate the 736delivery of ISCOMATRIX adjuvanted influenza vaccine via 737 738 its mucosal site of infection for improved vaccine effectiveness. Upon pulmonary immunization with low antigen doses 739 $(0.04 \ \mu g)$ of adjuvanted influenza equivalent serum antibody 740levels were induced when compared to an almost 375-fold 741 742 higher dose (15 µg) unadjuvanted influenza delivered subcutaneously suggesting the successful use of this combination for 743improved protection (101). 744

DRY POWDER PREPARATION TECHNIQUES 745

The use of liquid suspensions of NPs are often accompanied by 746 several disadvantages such as particle aggregation and sedi-747 mentation leading to physico-chemical instability, reduced or 748 loss of biological activity of the drug, contamination, and 749 hydrolysis leading to degradation of the polymer (102). To 750 overcome these problems, preparations can be stored and 751transported in a dry form (102). In addition, for vaccines, the 752delivery of a dry powder by inhalation has the potential benefits 753 of a) increased stability during transport and administration, b) 754increased safety by eliminating contamination risks and c) 755improved cost-effectiveness (103). The most commonly used 756methods for transforming liquid preparations into dry powders 757 are freeze-drying, spray-drying, spray-freeze-drying and the 758use of super critical fluid technologies. Each of these methods 759has advantages and disadvantages and are selected depending 760 on the desired attributes such as narrow particle size 761

Table VI List of Adjuvants in Either Development, Testing or for $\ t6.1$ Human Use

Category	Examples	t6.
Mineral Salts	Aluminium hydroxide (Alum)	t6.:
	Potassium aluminium sulphate	t6.4
	Aluminium phosphate	t6.5
Oil emulsions	MF59	t6.6
Particulate adjuvants	Virosomes	t6.7
	ISCOMS (Immuno stimulating complexes)	t6.8
Microbial derivatives	Monophosphoryl lipid A-MPL ^(TM)	t6.9
Plant derivatives	QS-21 (Saponin)	t6.1
	ADVAX	t6.1
Miscellaneous	AS04 (liposome formulation containing MPLA & QS-21), polymeric adjuvants, CpG oligodeoxynucleotides, vitamins	t6.1

distribution, improved bioavailability, enhanced stability, im-proved dispersibility and controlled release (104,105).

764 Freeze-Drying

Freeze-drying, also known as lyophilisation, is commonly used 765766 in industry to ensure long term stability and preservation of the 767 original properties of various biological products such as viruses, vaccines, proteins, peptides and their carriers; NPs and lip-768 769osomes (102,106). This process comprises of removing water 770 from a frozen sample by sublimation and desorption under 771 vacuum (106) and can be divided into three steps: freezing (solidification), primary drying (ice sublimation) and secondary 772 drying (desorption of unfrozen water) (102). However, this 773 process is relatively slow, very expensive and generates various 774 stresses on the biological product during both the freezing and 775 776 drying steps (106). Protectants in the form of excipients are 777 usually added to stabilize the products, avoid aggregation and 778 to ensure acceptable tonicity and reconstitution (106, 107). Sug-779 ars such as glucose, sucrose, trehalose, mannitol, lactose, dextran or maltose with or without surfactants such as poly(vinyl) alcohol 780 or poloxamer 188 are often employed as protectants to stabilize 781782 the product and prevent coalescence (107,108). The concentration and the NP/sugar mass ratio also play an important role in 783784 determining the stability and long term storage of the final 785product (102). Anhorn MG et al. evaluated the effect of different concentrations of sucrose, mannitol and trehalose as cryopro-786787 tectants on the physico-chemical characteristics of resulting NPs 788 by analyzing the appearance, particle-size and polydispersity 789 index (107). Long term stability studies indicated that the absence of cryoprotectants led to particle growth whereas their 790 791 presence reduced aggregation. Particles freeze-dried with sucrose and trehalose at 2% and 3%w/v had more controlled 792 793 particle size and these sugars appeared to be superior to man-794 nitol at similar concentrations (107).

795 Spray-Drying

796 Spray-drying is a one-step preparation of dry powders. It is a process that converts liquid feed (solution, suspension or col-797 798 loidal dispersion) into dry particles (109). The process can be divided into four parts (110): atomization (1), spray-air contact 799(2), drying (3) and separation (4). The liquid feed is atomized 800 801 (1) to break the liquid into droplets and this spray form comes into contact with a hot gas (2), causing rapid evaporation of 802 the droplets to form dry particles (3). The dry particles are 803 then separated from the hot gas with the help of a cyclone (4)804 (105). Compared to particles obtained from micronization 805 using milling, spray-dried particles are more spherical and 806 807 have a homogenous size-distribution resulting in a higher 808 respirable fraction which is advantageous for pulmonary de-809 livery (105). In addition, spray-drying has the advantage of being; simple, easily scalable, cost-effective, suitable for heat-810

sensitive products and enables high drug loading (110). An 811 economically acceptable yield can now be achieved with the 812 fourth and newest generation of laboratory-scale spray dryer 813 developed by Büchi, the Nano Spray Dryer B-90. This nano 814 spray dryer can generate particles of size ranging from 300 nm 815 to 5 µm for milligram sample quantities at high yields (up to 816 90%) (111). However, there is a chance of degradation of 817 macromolecules during the process due to high shear stress 818 in the nozzle and thermal stress while drying (105). Fourie PB 819 et al. (21) describes the challenges such as thermal stress, 820 osmotic stress, and scalability involved with spray-drying of 821 vaccines. Fourie PB et al. formulated a dry powder TB vaccine 822 for delivery to the lung by preparing Mycobacterium bovis Bacillus 823 Calmette-Guérin (BCG) spray-dried particles which, when 824 administered into M. tuberculosis infected guinea-pigs, resulted 825 in enhanced immunogenicity levels compared to an equal dose 826 injected subcutaneously into control animals (21). 827

Spray-Freeze Drying

828

857

Spray-freeze drying (SFD) is a drying process that usually 829 involves atomization, rapid freezing and lyophilisation (112). 830 A solution containing the drug is sprayed into a vessel that 831 contains a cryogenic liquid such as nitrogen, oxygen or argon. 832 As the boiling temperatures of these cryogenic liquids are very 833 low they cause the droplets to freeze instantly. The resulting 834 droplets are then collected and lyophilized to obtain porous dry 835 powder particles suitable for respiration (105). The advantage 836 of SFD is the ability to produce particles with adjustable sizes 837 (112) and as it is conducted at sub-ambient temperature, ther-838 molabile polymers and highly potent biopharmaceuticals can 839 be formulated into dry powder products (105). However, the 840 major disadvantage of this technique is the stresses associated 841 with freezing and drying, which may cause irreversible damage 842 to proteins (113). This is displayed as structural denaturation, 843 aggregation and loss of biological activity upon rehydration 844 (105). In addition, loss of stability due to unfolding and aggre-845 gation remains a major challenge (113) and also the method has 846 low process efficacy, is time consuming, and expensive (114). 847

Amorij J-P et al. showed that an influenza subunit vaccine 848 powder prepared by SFD using oligosaccharide inulin as a 849 stabilizer and delivered via the pulmonary route to BALB/c 850 mice induced systemic humoral (IgG), cell-mediated (II-4, 851 IFN- γ) and mucosal immune responses (IgA, IgG). Whereas 852 vaccination with a liquid subunit vaccine via either pulmonary 853 or intramuscular route induced only systemic humoral (IgG) 854 immune responses suggesting that powder vaccine formula-855 tions could be beneficial for immunization (23). 856

Supercritical Fluid Technology

Supercritical fluids (SCF) are compressed gases or liquids above 858 their critical temperatures (Tc) and pressures (Pc), and possess 859

Nanocarriers Targeting Pulmonary Dendritic Cells

860 several advantages of both gases and liquids (105). The density and thus solvating power can be controlled by varying the 861 temperature and pressure. SCF can be prepared using carbon 862 863 dioxide (CO_2) , water, propane, acetone, nitrous oxide (N_2O) , 864 trifluoromethane, chlorodifluoromethane, diethyl ether, water, or CO_2 with ethanol (114). However, because of its accessible 865 866 critical point at 31°C and 74 bar, its low cost and non-toxicity, CO_2 is the most widely used solvent in SCF. In addition, its 867 low critical temperature makes supercritical (SC) CO₂ suitable 868 for handling heat-labile solutes at conditions close to room 869 870 temperature. Therefore, SC CO₂ has potential as an alterna-871 tive to conventional organic solvents for use in solvent-based processes for forming solid dosage forms (105). 872

There are two major principles for particle precipitation 873 with supercritical fluids. One employs SCF as a solvent and 874 the other as an antisolvent (115). In the first, the drug is 875 dissolved in the SCF followed by sudden decompression, after 876 877 which the solution is passed through an orifice and rapidly 878 expanded at low pressure. Rapid Expansion of a Supercritical Solution (RESS) employs this principle (114). In the second 879 process, the solute is insoluble in SCF and hence utilizes SCF 880 as an antisolvent. A solute is dissolved in an organic solvent 881 882 and then precipitated by the SCF (antisolvent). Precipitation occurs when the SCF is absorbed by the organic solvent 883 followed by expansion of the liquid phase and a decrease in 884 885 the solvation power leading to particle formation. The Gas Anti-Solvent (GAS), Aerosol Solvent Extraction System 886 (ASES), Supercritical Fluid Antisolvent (SAS), Precipitation 887 with Compressed Antisolvent (PCA), Solution Enhanced Dis-888 persion by Supercritical Fluids (SEDS), and supercritical fluid 889 extraction of emulsion (SFEE) are the processes that employ 890 this second principle (114). Using these techniques particles 891can be formed in a well-ordered fashion to achieve the desired 892 morphology and any negative effects on the macromolecules 893 894 can be minimized (105,113). Thorough discussions of these 895 techniques including their advantages and disadvantages have

t7.1 **Table VII** Recent studies on dry powder particle-based vaccine delivery

been recently published by Al-fagih I *et al.* (114) and elsewhere 896 (105,113,115–118). 897

The fine powders produced via SCF precipitation are often 898 less charged than those produced mechanically allowing them 899 to flow more freely and thus to be more easily dispersed from a 900 DPI. In addition, SCF processes allow the production of inhal-901 able particles that are more uniform in terms of crystallinity, 902 morphology, particle-size distribution and shape than those 903 produced via jet milling. In spite of its potential, SCF is still 904 classified as an emerging technology that is still to be exploited 905in DPI products; with concerns being raised over the potential 906 denaturing effects of the solvents/antisolvents used in this pro-907 cess (105). Amidi M et al. prepared diphtheria toxoid (DT) 908 containing microparticles using a supercritical fluid (SCF) 909 spraying process and obtained dry powder microparticles with 910 a median volume diameter between 2 and 3 µm. Pulmonary 911 immunization of guinea pigs with DT-TMC (N-Trimethyl 912 chitosan) microparticles resulted in a strong immunological 913 response as reflected by the induction of IgM, IgG, IgG1 and 914 IgG2 antibodies comparable to or significantly higher than 915those achieved after subcutaneous (SC) administration of 916 alum-adsorbed DT demonstrating an effective new delivery 917 system for pulmonary administered DT antigen (119). 918

Table VII highlights some recent studies that have919employed various dry powder preparation techniques and920the subsequent evaluation for vaccine delivery.921

CONCLUSION

Pulmonary administration has gained significant attention 923 in the recent years as a potential non-invasive route for 924 vaccines, and has also shown great promise as an effective 925 means of vaccination. Much of the success is due to the 926 lung's large surface area (80 sq. m), and rich blood supply 927 leading to rapid absorption coupled with an abundance of 928

	Disease	Antigen	Carrier/Stabilizer	Dry Powder Preparation	Size (µm)	Model	Ref
	Bacterial Infections	Bacteriophages	Trehalose, Leucine	SD	2.5–2.8	NA	(32)
	Diptheria	Diptheria Toxoid	Chitosan	SCF	3–4	GP	(9)
	Diptheria	Diphtheria CRM-197 antigen	L-leucine	SD	~ 5	GP	(32)
	Hepatitis B	Recombinant hepatitis B surface antigen (rHBsAg)	Leucine	SD	4.8	GP	(75)
	Influenza	Influenza monovalent	Inulin	SD, SFD	2.6 (SD), 10.5 SFD)	Μ	(133)
	Influenza	Influenza subunit	Inulin	SFD	~ 10	Μ	(23)
	Tuberculosis	Ad35-vectored tuberculosis (TB) AERAS-402	Mannitol-cyclodextrin- trehalose-dextran, MCTD	SD	3.2–3.5	NA	(134)
)	Tuberculosis	Bacille Calmette-Guerin (BCG)	Leucine	SD	2–3	GP	(135)
1	Tuberculosis	Recombinant antigen 85B (rAg85B)	NA	SD	2.8	GP	(136)

SD Spray drying, SFD Spray-freeze drying, SCF Supercritical Fluid; M Mice, GP Guinea Pigs; NA Not Available

JmilD 11095 ArtiD 891 Proof# 1 21)09/2012

929 local APCs that present antigen in a way to induce both mucosal and systemic immune response. Recent progress in 930 targeting vaccines specifically to DCs for an enhanced im-931 932 mune response with low doses has paved way for developing 933 new vaccine technology. Polymer-based NPs offer the advantage of biodegradabiltiy, avoiding antigen degradation if 934 935 encapsulated and through chemical attachments can target DCs. However, more research is needed to understand the 936 fate of NPs after inhalation, their interaction with the biolog-937 938 ical cells and their toxicity (nanotoxicity). The method of 939 formulation of NP based vaccines into dry powders is of equal 940 importance as it provides the opportunity to maintain the 941 stability and integrity of the antigen, ease of transport and administration. The right combination of polymer chemistry, 942polymer-based NPs, immunology, dry powder technology, 943 944 delivery device and animal models will lead to the discovery

of next generation of vaccine delivery systems. 945

REFERENCES 946

948	1.	Brown LR. Commercial challenges of protein drug delivery.
949		Expet Opin Drug Deliv. 2005;2:29–42.
950	2.	Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B. Noninvasive
951		delivery technologies: respiratory delivery of vaccines. Expet Opin
952		Drug Deliv. 2006;3:87–95.
953	3.	Sou T, Meeusen EN, de Veer M, Morton DAV, Kaminskas LM,
954		McIntosh MP. New developments in dry powder pulmonary
955		vaccine delivery. Trends Biotechnol. 2011;29:191-8.
956	4.	Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E.
957		Physicochemical parameters associated with nanoparticle forma-
958		tion in the salting-out, emulsification-diffusion, and nanoprecipita-
959		tion methods. Pharm Res. 2004;21:1428–39.
960	5.	Rossi S, Sandri G, Caramella C. Buccal delivery systems for
961		peptides: recent advances. Am J Drug Deliv. 2005;3:215-25.
962	6.	Shojaei AH, Chang RK, Guo X, Burnside BA, Couch RA.
963		Systemic drug delivery via the buccal mucosal route. Pharm
964		Tech:70–81 (2001).
965	7.	Kumria Rand GG. Emerging trends in insulin delivery: Buccal
966		route. J Diabetol. 2011;2:1–9.
967	8.	Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular
968		weight drugs. Molecules. 2009;14:3754–79.
969	9.	Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug
970		delivery, I Control Release, 2011:153:106–16.

- delivery. J Control Release. 2011;153:106-16. 10. Kalluriand H, Banga A, Transdermal delivery of proteins. AAPS
- 971 972PharmSciTech. 2011;12:431-41.
- 11. Carstens MG. Opportunities and challenges in vaccine delivery. 973974 Eur J Pharm Sci. 2009;36:605-8.
- 975 12. Maurice J, Davey S. State of the world's vaccines and immuni-976 zation. http://www.unicef.org/media/files/SOWVI full 977 report english LR1.pdf (accessed 17/02/2012 2012).
- 97813. W.H. Organization. World Health Statistics 2011 in WHO 979 Statistical Information System (WHOSIS). http:// 980 www.who.int/whosis/whostat/2011/en/index.html (accessed 981 17/04 2012).
- 98214. Blank F, Stumbles P, von Garnier C. Opportunities and chal-983 lenges of the pulmonary route for vaccination. Expet Opin Drug 984Deliv. 2011;8:547-63.
- 985 15. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat 986 Med (2005).

1015

1016

- 16. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The 987 role of inhalant delivery devices and drug formulations in therapeu-988 tic effectiveness of aerosolized medications. Br J Clin Pharmacol. 989 990 2003:56:600-12 991
- 17. Sanders M. Inhalation therapy: an historical review. Prim Care Respir I. 2007:16:71-81. 992
- 18. Mack GS. Pfizer dumps Exubera. Nat Biotech. 2007;25:1331-2. 993 19. Onoue S, Hashimoto N, Yamada S. Dry powder inhalation systems 994 995 for pulmonary delivery of therapeutic peptides and proteins. Expert
- Opin Ther Pat. 2008;18:429-42. 996 20. de Swart RL, LiCalsi C, Quirk AV, van Amerongen G, 997 Nodelman V, Alcock R, et al. Measles vaccination of macaques 998
- 999 by dry powder inhalation. Vaccine. 2007;25:1183-90. 21. Fourie P, Germishuizen W, Wong Y-L, Edwards D. Spray drying 1000 TB vaccines for pulmonary administration. Expert Opin Biol 1001 Ther. 2008;8:857-63. 1002
- 22. LiCalsi C, Maniaci MJ, Christensen T, Phillips E, Ward GH, 1003 Witham C. A powder formulation of measles vaccine for aerosol 1004 delivery. Vaccine. 2001;19:2629-36. 1005
- 23. Amorij JP, Saluja V, Petersen AH, Hinrichs WLJ, Huckriede A, 1006 Frijlink HW. Pulmonary delivery of an inulin-stabilized influenza 1007 1008 subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in 1009 BALB/c mice. Vaccine. 2007;25:8707-17. 1010
- 24. Thomas C, Rawat A, Hope-Weeks L, Ahsan F. Aerosolized PLA 1011 and PLGA Nanoparticles Enhance Humoral. Mucosal and 1012 Cytokine Responses to Hepatitis B Vaccine. Mol Pharm. 2010; 1013 8:405-15. 1014
- 25. Effros RM. Anatomy, development, and physiology of the lungs. GI Motility online. 1: (2006).
- 26. Kleinstreuer C, Zhang Z, Li Z. Modeling airflow and particle 1017 1018 transport/deposition in pulmonary airways. Respir Physiol Neurobiol. 2008;163:128-38. 1019
- 27. Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol 1020 delivery in the human respiratory system. Annu Rev Biomed 1021 1022 Eng. 2008;10:195-220. 1023
- 28. Gehr P. Annexe A. Anatomy and morphology of the respiratory tract. Ann ICRP. 1994;24:121-66.
- 29. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical per-1025spectives on pulmonary systemic and macromolecular delivery. Adv 1026Drug Deliv Rev. 2006;58:996-1008. 1027
- 30. Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, 1028 Holmgren J. Systemic and Mucosal Immune Responses in Mice 1029 after Mucosal Immunization with Group B Streptococcus Type 1030 1031III Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate 1032Vaccine. Infect Immun. 2000;68:5749-55.
- 31. Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, 1033 Pasquier M, et al. Nanoparticle conjugation and pulmonary de-10341035livery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine. 2011;29:6959-66. 1036
- 32 Muttil P, Pulliam B, Garcia-Contreras L, Fallon J, Wang C, 1037Hickey A, et al. Pulmonary immunization of Guinea Pigs with 1038 diphtheria CRM-197 antigen as nanoparticle aggregate dry pow-10391040 ders enhance local and systemic immune responses. AAPS J. 2010:12:699-707. 1041
- 33. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. 1042Biodegradable mucoadhesive particulates for nasal and pulmo-1043 nary antigen and DNA delivery. Adv Drug Deliv Rev. 10441045 2005;57:411-30.
- 34. Vermaelen K, Pauwels R. Pulmonary Dendritic Cells. Am J 1046 Respir Crit Care Med. 2005;172:530-51. 1047
- 35. Banchereau J, Steinman RM. Dendritic cells and the control of 1048 1049 immunity. Nature. 1998;392:245-52.
- 36. Nobelprize.org. The Nobel Prize in Physiology or Medicine 1050 10512011. http://www.nobelprize.org/nobel prizes/medicine/ laureates/2011/ (accessed 19 Apr 2012). 1052

1123

1125

Nanocarriers Targeting Pulmonary Dendritic Cells

1053	37. Lassila O, Vainio O, Matzinger P. Can B cells turn on virgin T
1054	cells? Nature. 1988;334:253-5.
1055	38. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y-J,

- 1056 et al. Immunobiology of Dendritic Cells. Annu Rev Immunol. 1057 2000:18:767-811.
- 105839. Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. 1059Antigen Presentation and T Cell Stimulation by Dendritic Cells. 1060 Annu Rev Immunol. 2002;20:621-67.
- 1061 40. Foged C, Sundblad A, Hovgaard L. Targeting Vaccines to 1062Dendritic Cells. Pharm Res. 2002;19:229-38.
- 1063 41. Lambrecht BN, Hammad H. Biology of Lung dendritic cells at 1064the origin of asthma. Immunity. 2009;31:412-24.
- 106542. GeurtsvanKessel CH, Lambrecht BN. Division of labor between 1066 dendritic cell subsets of the lung. Mucosal Immunol. 2008;1:442-1067 50
- 1068 43. Lommatzsch M, Bratke K, Bier A, Julius P, Kuepper M, 1069Luttmann W, et al. Airway dendritic cell phenotypes in inflam-1070 matory diseases of the human lung. Eur Respir J. 2007;30:878-86. 1071
- 1072 44. Ba-Omar T, Al-Riyami B. Microscopic study of human alveolar 1073macrophages. Microsc Microanal. 2008;14:1518-9.
- 107445. Kiama SG, Cochand L, Karlsson L, Nicod LP, Gehr P. 1075Evaluation of phagocytic activity in human monocyte-derived 1076dendritic cells. J Aerosol Med. 2001;14:289-99.
- 1077 46. von Garnier C, Nicod LP. Immunology taught by lung dendritic 1078cells. Swiss Med Wkly. 2009;139:186-92.
- 107947. Demedts IK, Brusselle GG, Vermaelen KY, Pauwels RA. 1080 Identification and characterization of human pulmonary dendrit-1081 ic cells. Am J Respir Cell Mol Biol. 2005;32:177-84.
- 108248. Gallucci S, Matzinger P. Danger signals: SOS to the immune 1083system. Curr Opin Immunol. 2001;13:114-9.
- 1084 49. Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck 1085F, et al. Liposomal delivery of antigen to human dendritic cells. 1086 Vaccine. 2003;21:883-90.
- 1087 50. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor 1088 mediates uptake of soluble but not of cell-associated antigen for 1089cross-presentation. J Immunol. 2006;176:6770-6.
- 1090 51. Platt CD, Ma JK, Chalouni C, Ebersold M, Bou-Reslan H, Carano 1091 RAD, et al. Mature dendritic cells use endocytic receptors to capture 1092 and present antigens. Proc Natl Acad Sci. 2010;107:4287-92.
- 1093 52. Thornton EE, Looney MR, Bose O, Sen D, Sheppard D, 1094 Locksley R, Huang X, Krummel MF. Spatiotemporally separat-1095 ed antigen uptake by alveolar dendritic cells and airway presen-1096 tation to T cells in the lung. The Journal of Experimental 1097 Medicine (2012).
- 1098 53. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and 1099 surface charge affect particle uptake by human dendritic cells in 1100 an in vitro model. Int J Pharm. 2005;298:315-22.
- 1101 54. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, 1102 Bachmann MF. Nanoparticles target distinct dendritic cell pop-1103ulations according to their size. Eur J Immunol. 2008;38:1404-1104 13.
- 110555. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells 1106 with biomaterials: developing the next generation of vaccines. 1107 Trends Immunol. 2006;27:573-9.
- 1108 56. Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor 1109CG. Comparison of antibodies and carbohydrates to target vac-1110cines to human dendritic cells via DC-SIGN. Biomaterials. 11112012;33:4229-39.
- 1112 57. Caminschi I, Maraskovsky E, Heath WR. Targeting dendritic 1113 cells in vivo for cancer therapy. Frontiers in Immunology. 3: 1114(2012).
- 58. Carrillo-Conde B, Song E-H, Chavez-Santoscoy A, Phanse Y, 11151116 Ramer-Tait AE, Pohl NLB, et al. Mannose-functionalized 1117 "Pathogen-like" polyanhydride nanoparticles target c-type lectin 1118 receptors on dendritic cells. Mol Pharm. 2011;8:1877-86.

- 59. Geijtenbeek TBH, Gringhuis SI. Signalling through C-type lectin 1119 1120 receptors: shaping immune responses. Nat Rev Immunol. 2009; 9:465-79. 11211122
- 60. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25:563-70.
- 61. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmo-1124nary drug delivery. Med Res Rev. 2009;29:196-212.
- 112662. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmo-1127 nary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine. 2008;3:1-19. 1128
- 63. Smyth HDC, Smyth HH, Hickey AJ. Macro and Microstructure of the 1129Airways for Drug Delivery in Controlled Pulmonary Drug Delivery, 1130Springer, 2011. 1131
- 64. Heffernan MJ, Kasturi SP, Yang SC, Pulendran B, Murthy N. 1132The stimulation of CD8+ T cells by dendritic cells pulsed with 1133 polyketal microparticles containing ion-paired protein antigen 1134and poly(inosinic acid)-poly(cytidylic acid). Biomaterials. 11351136 2009:30:910-8.
- 65. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, 1137 Ficht TA. Polymeric particles in vaccine delivery. Curr Opin 1138 Microbiol. 2010;13:106-12. 1139
- 66. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug 1140 and gene delivery to cells and tissue. Adv Drug Deliv Rev. 1141 2003;55:329-47. 1142
- 67. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymer-1143ic nanocarriers for pulmonary drug delivery. Expet Opin Drug 1144Deliv. 2008;5:629-39. 1145
- 68. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric 1146 nanoparticles based drug delivery systems. Colloids Surf B 1147 Biointerfaces. 2010;75:1-18. 1148
- 69. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vac-11491150 cine delivery systems for cancer therapy. Mol Cancer. 2011;10:3.
- 70 Doria-Rose NA, Haigwood NL. DNA vaccine strategies: candi-1151dates for immune modulation and immunization regimens. 1152Methods. 2003;31:207-16. 1153
- 115471. Bivas-Benita M, van Meijgaarden KE, Franken KLMC, Junginger HE, Borchard G, Ottenhoff THM, et al. Pulmonary 1155delivery of chitosan-DNA nanoparticles enhances the immuno-1156genicity of a DNA vaccine encoding HLA-A*0201-restricted T-1157cell epitopes of Mycobacterium tuberculosis. Vaccine. 2004; 115822:1609-15. 1159
- 72. Jain JRA. The manufacturing techniques of various drug loaded 1160 biodegradable poly(lactide-co-glycolide) (PLGA) devices. 1161Biomaterials. 2000;21:2475-90. 1162
- 116373. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5-24. 1164
- 74. Fiore VF, Lofton MC, Roser-Page S, Yang SC, Roman J, 1165Murthy N, et al. Polyketal microparticles for therapeutic delivery 1166 1167to the lung. Biomaterials. 2010;31:810-7.
- 75. Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon J, Wang 1168 C, et al. Immunization of Guinea Pigs with Novel Hepatitis B 11691170 Antigen as Nanoparticle Aggregate Powders Administered by the Pulmonary Route. AAPS J. 2010;12:330-7. 1171
- 76. Heffernan MJ, Murthy N. Polyketal nanoparticles: a new pH-1172sensitive biodegradable drug delivery vehicle. Bioconjug Chem. 1173 2005;16:1340-2. 1174
- 77. Yang SC, Bhide M, Crispe IN, Pierce RH, Murthy N. Polyketal 11751176copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjug Chem. 2008;19:1164-9. 1177
- 78. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation 1178 I. Methods for preparation of drug-loaded polymeric nano-1179particles. Nanomedicine Nanotechnol Biol Med. 2006;2:8-1180 1181 21.
- 79. Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid 11821183 loaded poly-(e-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods. 2006;38:96-105. 1184

1256

1257

1269

1270

1280

1281

1282

1283

1284

1285

1286

1287

1294

1295

1296

1297

1298

1299

- 118580. Mahapatro A, Singh D. Biodegradable nanoparticles are excel-1186 lent vehicle for site directed in-vivo delivery of drugs and vaccines. 1187 J Nanobiotechnology. 2011;9:55.
- 1188 81. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. 1189Polylactide-co-glycolide nanoparticles for controlled delivery of 1190anticancer agents. Int J Nanomedicine. 2011;6:877-95.
- 1191 82. Lee JS, Hwang SJ, Lee DS, Kim SC, Kim DJ. Formation of Poly 1192(ethylene glycol)-Poly(e-caprolactone) Nanoparticles via 1193 Nanoprecipitation. Macromol Res. 2009;17:72-8.
- 119483. Ranjan AP, Zeglam K, Mukerjee A, Thamake S, Vishwanatha 1195IK. A sustained release formulation of chitosan modified PLCL: 1196 poloxamer blend nanoparticles loaded with optical agent for 1197 animal imaging. Nanotechnology. 2011;22:1-10.
- 1198 84. Allémann E, Gurny R, Doelker E. Preparation of aqueous poly-1199 meric nanodispersions by a reversible salting-out process: influ-1200ence of process parameters on particle size. Int J Pharm. 1201 1992;87:247-53.
- 1202 85. Muthu M. Nanoparticles based on PLGA and its co-polymer: An 1203 overview, 2009.
- 1204 86. Konan YN, Gurny R, Allémann E. Preparation and character-1205ization of sterile and freeze-dried sub-200 nm nanoparticles. Int J 1206 Pharm. 2002;233:239-52.
- 1207 87. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. 1208Biodegradable polymeric nanoparticles as drug delivery devices. J 1209 Control Release. 2001;70:1-20.
- 1210 88. Bivas-Benita M, Romeijn S, Junginger HE, Borchard G. PLGA-1211 PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm. 2004;58:1-6. 1212
- 1213 89. Bivas-Benita M, Lin MY, Bal SM, van Meijgaarden KE, Franken 1214KLMC, Friggen AH, et al. Pulmonary delivery of DNA encoding 1215Mycobacterium tuberculosis latency antigen Rv1733c associated 1216 to PLGA-PEI nanoparticles enhances T cell responses in a DNA 1217 prime/protein boost vaccination regimen in mice. Vaccine. 1218 2009;27:4010-7.
- 1219 90. Pulliam B, Sung JC, Edwards DA. Design of nanoparticle-based 1220 dry powder pulmonary vaccines. Expet Opin Drug Deliv. 1221 2007.4.651-63
- 1222 91. Allen TM, Cullis PR. Drug delivery systems: entering the main-1223stream. Science. 2004;303:1818-22.
- 122492. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and 1225future trends. Immunol Cell Biol. 2004;82:488-96.
- 122693. O'Hagan DT, MacKichan ML, Singh M. Recent developments 1227in adjuvants for vaccines against infectious diseases. Biomol Eng. 12282001;18:69-85.
- 94. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, 12291230Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 2009;98:1278-1232316.
- 123395. Amorij J-P, Kersten GFA, Saluja V, Tonnis WF, Hinrichs WLJ, 1234Slütter B, Bal SM, Bouwstra JA, Huckriede A, Jiskoot W. 1235Towards tailored vaccine delivery: Needs, challenges and per-1236spectives. Journal of Controlled Release.
- 1237 96. Sekaly R-P. The failed HIV Merck vaccine study: a step back or a 1238 launching point for future vaccine development? J Exp Med. 1239 2008.205.7-12
- 124097. Lewis DJM, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, 1241et al. Transient facial nerve paralysis (Bell's Palsy) following intra-1242nasal delivery of a genetically detoxified mutant of Escherichia coli 1243heat labile toxin. PLoS One. 2009;4:e6999.
- 124498. Vajdy M. Immunomodulatory properties of vitamins, flavonoids 1245and plant oils and their potential as vaccine adjuvants and deliv-1246ery systems. Expert Opin Biol Ther. 2011;11:1501-13.
- 124799. Skountzou I, Quan F-S, Jacob J, Compans RW, Kang S-M. 1248 Transcutaneous immunization with inactivated influenza virus 1249 induces protective immune responses. Vaccine. 2006;24:6110-12509.

- 100. Nottenburg C. Types of adjuvants: In Introduction to Adjuvant 12511252Patent Landscape. http://www.patentlens.net/daisy/adjuvants/ 1253Background/Adjuvant types.html (accessed 14th April 2012). 1254
- 101. Wee JLK, Scheerlinck JPY, Snibson KJ, Edwards S, Pearse M, Quinn C, et al. Pulmonary delivery of ISCOMATRIX influenza 1255vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol. 2008;1:489-96.
- 102. Vauthier C, Bouchemal K. Methods for the preparation and 12581259manufacture of polymeric nanoparticles. Pharm Res. 2009; 26:1025-58. 1260
- 103. LiCalsi C, Christensen T, Bennett JV, Phillips E, Witham C. Dry 1261powder inhalation as a potential delivery method for vaccines. 12621263 Vaccine. 1999;17:1796-803.
- 104. Mansour HM, Rhee Y, Wu X. Nanomedicine in pulmonary 1264 delivery. Int J Nanomedicine. 2009;4:299-319. 1265
- 105. Pilcer G, Amighi K. Formulation strategy and use of excipients in 1266 pulmonary drug delivery. Int J Pharm. 2010;392:1-19. 12671268
- 106. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58:1688-713.
- 107. Anhorn MG, Mahler H-C, Langer K. Freeze drying of human 12711272serum albumin (HSA) nanoparticles with different excipients. Int I Pharm. 2008:363:162-9. 1273
- 108. Hirsjärvi S, Peltonen L, Hirvonen J. Effect of sugars, surfactant, 1274and tangential flow filtration on the freeze-drying of Poly(lactic 1275acid) nanoparticles. AAPS PharmSciTech. 2009;10:488-94. 12761277
- 109. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharmaceut Sci Tech Today. 1998;1:394-8. 1278 1279
- 110. Peltonen L, Valo H, Kolakovic R, Laaksonen T, Hirvonen J. Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. Expet Opin Drug Deliv. 2010;7:705-19.
- Heng D, Lee SH, Ng WK, Tan RB. The nano spray dryer B-90. 111 Expet Opin Drug Deliv. 2011;8:965-72.
- 112. Amorij JP, Huckriede A, Wilschut J, Frijlink H, Hinrichs W. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25:1256-73.
- 1288 113. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009-29. 1289
- 1290 114. Al-fagih IM, Alanazi FK, Hutcheon GA, Saleem IY. Recent 1291 advances using supercritical fluid techniques for pulmonary administration of macromolecules via dry powder formulations. 1292 Drug Deliv Lett. 2011;1:128-34. 1293
- 115. Okamoto H, Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev. 2008;60:433-46.
- 116. Byrappa K, Ohara S, Adschiri T. Nanoparticles synthesis using supercritical fluid technology - towards biomedical applications. Adv Drug Deliv Rev. 2008;60:299-327.
- 117. Kenji M. Biodegradable particle formation for drug and gene 1300 delivery using supercritical fluid and dense gas. Adv Drug Deliv 1301Rev. 2008;60:411-32. 1302
- 118. Pasquali I, Bettini R, Giordano F. Supercritical fluid technolo-13031304 gies: an innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliv Rev. 2008;60:399-410. 1305
- 119. Amidi M, Pellikaan HC, Hirschberg H, de Boer AH, Crommelin 1306DJA, Hennink WE, et al. Diphtheria toxoid-containing micro-13071308particulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. 1309Vaccine. 2007;25:6818-29. 1310
- 120. W.H. Organization. Pneumonia. http://www.who.int/ 1311mediacentre/factsheets/fs331/en/index.html (accessed 17/04 1312 2012). 1313
- 121. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, 1314Lavasanifar A. Active targeting of dendritic cells with mannan-1315decorated PLGA nanoparticles. J Drug Target. 2011;19:281-92. 1316

Nanocarriers Targeting Pulmonary Dendritic Cells

- 1317 122. Bandvopadhvay A, Fine RL, Demento S, Bockenstedt LK, 1318 Fahmy TM. The impact of nanoparticle ligand density on 1319 dendritic-cell targeted vaccines. Biomaterials. 2011;32:3094-1320 105
- 1321123. Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio 1322F. et al. Targeted PLGA nano- but not microparticles specifically 1323 deliver antigen to human dendritic cells via DC-SIGN in vitro. J 1324Control Release. 2010;144:118-26.
- 1325124. Kwon YJ, James E, Shastri N, Fréchet JMJ. In vivo targeting of 1326dendritic cells for activation of cellular immunity using vaccine 1327 carriers based on pH-responsive microparticles. Proc Natl Acad 1328 Sci U S A. 2005;102:18264-8.
- 1329125. Kempf M, Mandal B, Jilek S, Thiele L, Vörös J, Textor M, et al. 1330 Improved stimulation of human dendritic cells by receptor en-1331 gagement with surface-modified microparticles. J Drug Target. 13322003.11.11-8
- 1333126. Sheng K-C, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, 1334 Apostolopoulos V, et al. Delivery of antigen using a novel man-1335nosylated dendrimer potentiates immunogenicity in vitro and in 1336 vivo. Eur J Immunol. 2008;38:424-36.
- 1337 127. White KL, Rades T, Furneaux RH, Tyler PC, Hook S. 1338Mannosylated liposomes as antigen delivery vehicles for tar-1339geting to dendritic cells. J Pharm Pharmacol. 2006;58:729-134037
- 1341 128. Jain S, Vyas SP. Mannosylated niosomes as adjuvant-carrier system 1342for oral mucosal immunization. J Liposome Res. 2006;16: 1343 331-45.
- 1371

- 129. Hao J, Kwissa M, Pulendran B, Murthy N. Peptide crosslinked 13441345micelles: a new strategy for the design and synthesis of peptide vaccines. Int J Nanomedicine. 2006;1:97-103. 1346
- 130. Luand D, Hickey AJ. Liposomal dry powders as aerosols for 1347 pulmonary delivery of proteins. AAPS PharmSciTech. 2005;6: 1348E641-8. 1349
- 131. Barnier Quer C, Robson Marsden H, Romeijn S, Zope H, Kros 1350 1351A, Jiskoot W. Polymersomes enhance the immunogenicity of influenza subunit vaccine. Polym Chem. 2011;2:1482-5. 1352
- 132. Matinkhoo S, Lynch KH, Dennis JJ, Finlay WH, Vehring R. Spray-1353dried respirable powders containing bacteriophages for the treat-1354ment of pulmonary infections. J Pharm Sci. 2011;100:5197-205. 1355
- 1356133 Saluja V, Amorij JP, Kapteyn JC, de Boer AH, Frijlink HW, Hinrichs WLJ. A comparison between spray drying and spray 1357 freeze drying to produce an influenza subunit vaccine powder for 1358inhalation. J Control Release. 2010;144:127-33. 1359
- 134. Jin TH, Tsao E, Goudsmit J, Dheenadhayalan V, Sadoff J. 13601361Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). Vaccine. 13622010;28:4369-75. 1363
- 135. Garcia-Contreras L, Wong Y-L, Muttil P, Padilla D, Sadoff J, 1364DeRousse J, et al. Immunization by a bacterial aerosol. Proc Natl 1365Acad Sci. 2008:105:4656-60. 1366
- 136. Lu D, Garcia-Contreras L, Muttil P, Padilla D, Xu D, Liu J, et al. 1367 Pulmonary Immunization Using Antigen 85-B Polymeric 1368 Microparticles to Boost Tuberculosis Immunity. AAPS J. 13692010;12:338-47. 1370

AUTHOR QUERY

AUTHOR PLEASE ANSWER QUERY.

No Query.

unconnection